AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02942017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of matching placebo for SAGE-547.
Trial: NCT04405245
Drug: AKB-9778 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Razuprotafib opthalmic solution
Trial: NCT04405245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for razuprotafib opthalmic solution
Trial: NCT01847456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03469323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
Trial: NCT01433354
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
Trial: NCT00163579
Drug: Bryophyllum
RxNorm normalized name: Bryophyllum (Argento Cultum)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00345982
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01171326
Drug: Topical Minocycline Foam FXFM244
RxNorm normalized name: minocycline Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
Trial: NCT01618162
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously (under the skin) once daily.
Trial: NCT02750254
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02625714
Drug: Renexin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
Trial: NCT02625714
Drug: SID142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
Trial: NCT03370562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of normal saline
Trial: NCT01844778
Drug: Tobramycin Inhalation Powder
RxNorm normalized name: Tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
Trial: NCT01532869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously weekly, Weeks 0-48
Trial: NCT02562807
Drug: Placebo 18mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02562807
Drug: Placebo 9mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04447326
Drug: IC＋CCRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC＋CCRT
Trial: NCT04133233
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
Trial: NCT03385928
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given within 2 hours of symptom onset
Trial: NCT04181385
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo capsules
Trial: NCT00889538
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL of 1/2 normal saline IV
Trial: NCT00889538
Drug: glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glutathione 600 mg IV
Trial: NCT00889538
Drug: glutathione, vit C and NAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
Trial: NCT00911534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
Trial: NCT00472563
Drug: Bicarbinate 150 mEq/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
Trial: NCT01589458
Drug: Toothpaste
RxNorm normalized name: TOOTHPASTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
Trial: NCT00814294
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule,0 units, quater in die (QID) for 18 weeks
Trial: NCT00814294
Drug: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
Trial: NCT00814294
Drug: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
Trial: NCT04702568
Drug: BCX9930
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCX9930 for oral administration
Trial: NCT00908154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets to match GSK1014802
Trial: NCT00908154
Drug: GSK1014802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium channel blocker
Trial: NCT02824133
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg bd (per os)
Trial: NCT03936192
Drug: glucosamine sulphate 1500mg and meloxicam 15mg
RxNorm normalized name: glucosamine hydrochloride 1500 MG
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
Trial: NCT01543139
Drug: Valproate+Cytidine-+Creatine-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
Trial: NCT00649441
Drug: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
RxNorm normalized name: hydrochlorothiazide / quinapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/25mg, single dose fasting
Trial: NCT00649441
Drug: Accuretic™ Tablets 20 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/25mg, single dose fasting
Trial: NCT03623425
Drug: 18F-FCH PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
Trial: NCT01357980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra detrusor injection on Day 1 (single dose)
Trial: NCT02722265
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
Trial: NCT00440830
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch applied to smokers
Trial: NCT00440830
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch applied to nonsmokers
Trial: NCT02951429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched with sildenafil.
Trial: NCT00753597
Drug: Solu-medrone, Mabthera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mg, 1gram, twice day 1 and day 15
Trial: NCT03936192
Drug: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
Trial: NCT03936192
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once daily for 12 weeks.
Trial: NCT03024255
Drug: BBI-4000 gel, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI-4000 gel, 5% applied once to each axilla daily
Trial: NCT03024255
Drug: BBI-4000 gel, 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI-4000 gel, 10% applied once to each axilla daily
Trial: NCT03024255
Drug: BBI-4000 gel, 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI-4000 gel, 15% applied once to each axilla daily
Trial: NCT00597415
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 200mg
Trial: NCT00597415
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00654953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose or lactose) administered twice per day for 12 weeks.
Trial: NCT03597087
Drug: Anesthesia
RxNorm normalized name: anesthesia tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia : propopol~Spinal anaesthesia : bupibacaine
Trial: NCT01277497
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium acetate 1,334 mg three times daily with meals for 12 weeks
Trial: NCT02283203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
Trial: NCT02836483
Drug: LCB01-0371 800mg, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02836483
Drug: LCB01-0371 400mg, BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02836483
Drug: LCB01-0371 800mg, BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02836483
Drug: Zyvox 600mg, BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02044861
Drug: PFK-158
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose escalation
Trial: NCT02836483
Drug: LCB01-0371 1200mg, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03220334
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group was treated with normal saline for artificial gastric ulcer after ESD.
Trial: NCT01147406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
Trial: NCT03867942
Drug: Monolayer group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monolayered combination of gemigliptin and rosuvastatin
Trial: NCT03867942
Drug: Bilayer group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilayered combination of gemigliptin and rosuvastatin
Trial: NCT02597140
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
Trial: NCT00417430
Drug: ICI 182,780 (Faslodex)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00333918
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01772836
Drug: RPX7009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
Trial: NCT01772836
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
Trial: NCT03310385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT04839120
Drug: MDPK67b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two subgroups (Panels A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
Trial: NCT04839120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two subgroups (Panel A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
Trial: NCT01093586
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01770899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsule given every 24 hours
Trial: NCT00788710
Drug: etoricoxib (MK0663) 120 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of etoricoxib (MK0663) for a total of 5 days
Trial: NCT00105989
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00788710
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Trial: NCT02159261
Drug: BAY98-7071_EE20/DRSP/L-5-MTHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated by Physicians under approved local prescriptions
Trial: NCT02483689
Drug: Pre Incisional Local Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
Trial: NCT01185704
Drug: Recombinant Human Choriogonadotropin (r-hCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
Trial: NCT00159159
Drug: Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02939599
Drug: QCC374
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015mg and 0.06mg
Trial: NCT00788710
Drug: etoricoxib (MK0663) 90 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of etoricoxib (MK0663) for a total of 5 days
Trial: NCT03082053
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Companion Medication
Trial: NCT03908970
Drug: 1% OPA-15406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT03908970
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT02839941
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive glucocorticoids for consecutive 52 weeks
Trial: NCT03154541
Drug: Synrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
Trial: NCT02741219
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group receives normal saline bolus after delivery
Trial: NCT02741219
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil PCA after surgery
Trial: NCT02741219
Drug: Sufentanil and dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil combined with dexmedetomidine PCA after surgery
Trial: NCT02133742
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
Trial: NCT02235402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02472795
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Trial: NCT02192502
Drug: human albumin 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00475800
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03812588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
Trial: NCT01725256
Drug: AIR001 (sodium nitrite inhalation solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose arms specify dose loaded into the I-neb AAD System nebulizer
Trial: NCT00003893
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003893
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003893
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003893
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003893
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01392378
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Trial: NCT01392378
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
Trial: NCT00788697
Drug: SonoVue-enhanced ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
Trial: NCT00108797
Drug: Feiba VH
RxNorm normalized name: Feiba VH Immuno
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02564029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for PF-06372865 and placebo for lorazepam
Trial: NCT03627494
Drug: GSK3439171A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Trial: NCT03627494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Trial: NCT03649334
Drug: ketamine-ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
Trial: NCT03649334
Drug: fentanyl- ketorolac
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
Trial: NCT03686696
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
Trial: NCT03686696
Drug: ACEI
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.